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Abstract
Objectives Traditional contrast-enhanced methods for scan-
ning blood vessels using magnetic resonance imaging (MRI)
or CT carry potential risks for patients with advanced kidney
disease. Ferumoxytol is a superparamagnetic iron oxide nano-
particle preparation that has potential as anMRI contrast agent
in assessing the vasculature.
Methods Twenty patients with advanced kidney disease re-
quiring aorto-iliac vascular imaging as part of pre-operative
kidney transplant candidacy assessment underwent
ferumoxytol-enhanced magnetic resonance angiography
(FeMRA) between December 2015 and August 2016. All
scans were performed for clinical indications where standard
imaging techniques were deemed potentially harmful or in-
conclusive. Image quality was evaluated for both arterial and
venous compartments.
Results First-pass and steady-state FeMRA using incremental
doses of up to 4 mg/kg body weight of ferumoxytol as intra-
venous contrast agent for vascular enhancement was per-
formed. Good arterial and venous enhancements were
achieved, and FeMRA was not limited by calcification in
assessing the arterial lumen. The scans were diagnostic and
all patients completed their studies without adverse events.
Conclusions Our preliminary experience supports the feasi-
bility and utility of FeMRA for vascular imaging in patients
with advanced kidney disease due for transplant listing, which
has the advantages of obtaining both arteriography and venog-
raphy using a single test without nephrotoxicity.
Key Points
• Evaluation of vascular disease is important in planning kid-
ney transplantation.
• Standard vascular imaging methods are often problematic in
kidney disease patients.
• FeMRA has the advantage of arteriography and venography
in a single test.
• FeMRA is safe and non-nephrotoxic.
• FeMRA is not limited by arterial calcification.
Keywords Magnetic resonance imaging . Kidney failure,
chronic . Kidney transplantation . Angiography . Ferric
compounds
Abbreviations
CCI Charlson Comorbidity Index
ERF Established renal failure
FeMRA Ferumoxytol-enhanced magnetic resonance
angiography
MDRD Modification of diet in renal disease
NSF Nephrogenic systemic fibrosis
USPIO Ultrasmall superparamagnetic iron oxide
Introduction
Kidney transplant candidates often require accurate assess-
ment of their vascular anatomy before being wait-listed for
transplantation. Imaging studies with vascular mapping can
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assess arterial and venous anatomy, thereby establishing
whether kidney transplantation is possible, whether
presurgical procedures are necessary, and which is the best
surgical technique for each candidate. Conventional vascular
imaging techniques are often problematic in kidney disease
patients due to associated risks, invasiveness and imprecision.
Computed tomography angiography (CTA) entails radiation
exposure and the use of iodine-based contrast that may pre-
cipitate a deterioration in kidney function or even the need for
renal replacement therapy [1, 2]. Magnetic resonance angiog-
raphy (MRA) in patients with advanced kidney disease using
linear gadolinium-based contrast agents (GBCAs) has been
associated with the rare disease nephrogenic systemic fibrosis
(NSF) [3]. Alternative imaging methods also have drawbacks;
for example, Doppler ultrasound (US) is a potentially useful
modality but can be difficult to interpret and is vulnerable to
high inter- and intra-operator variability and patient habitus.
This patient group has a higher risk of complications from
conventional catheter-based x-ray angiography, and non-
contrast-enhanced MRA (e.g. time-of-flight or phase-
contrast techniques) is very time consuming for assessment
of multidirectional flow with poor signal from deep vascular
structures and at the sites of flow disturbance.
Ferumoxytol is a solution of ultrasmall superparamagnetic
iron oxide (USPIO) particles encapsulated by a semisynthetic
carbohydrate that prevents redistribution outside the vascular
space. Ferumoxytol was initially developed as a magnetic
resonance imaging (MRI) contrast agent in 2000 [4].
However, it was first licensed as a therapeutic agent for the
treatment of iron deficiency anaemia (IDA) in patients with
chronic kidney disease (CKD) [5]. Recently, ferumoxytol has
regained appeal as an MRI contrast agent in patients with
estimated glomerular filtration rates (eGFR) <30 ml/min/
1.73 m2.
We report our findings in 20 patients with severely im-
paired renal function or on dialysis who underwent ‘off-label’
ferumoxytol-enhanced MRA (FeMRA) for vascular evalua-
tion prior to being wait-listed for kidney transplantation.
Materials and methods
Study population
Patients more than 18 years of age with advanced kidney
disease or on dialysis attending transplant assessment clinics
in Glasgow and requiring vascular imaging prior to wait-
listing for kidney transplantation were included in this series.
Criteria for vascular imaging included intermittent claudica-
tion, known peripheral vascular disease (PVD) with previous
angioplasty or revascularisation procedure or leg amputation,
extensive disease in other vascular beds, and the presence of
risk factors for PVD (diabetes, smoking, hypertension,
obesity). In some instances, patients had FeMRA in addition
to prior conventional CTA if the clinician felt that additional
investigation was required to characterise the vessels before
placement of a kidney graft. These were usually patients who
had blooming artefacts from dense calcifications on initial
CTA. Dialysis patients were included if there was evidence
of extensive vascular calcification or they had residual renal
function with a risk of accelerated decline in function after
CTA. Patients with standard contraindications to MRI (such
as non-MRI-compatible pacemakers, severe claustrophobia
and metal in the eyes), history of allergic reaction to any in-
travenous iron product, any conditions associated with iron
overload, and patients with active immune or inflammatory
conditions (e.g. systemic lupus, rheumatoid arthritis) were ex-
cluded. This evaluation of the use of ferumoxytol as a new
potential clinical service was approved by the Clinical
Governance Committee of the Diagnostics Directorate of
NHS Greater Glasgow & Clyde. In this context, the West of
Scotland Research Ethics Committee ethics officer was
consulted and confirmed that no formal ethics committee ap-
proval was required. Nevertheless, as this was an off-label use
of the agent, informed consent was obtained from all subjects.
Investigations were performed between 1 December 2015 and
1 August 2016.
Baseline data
Age, gender, aetiology of established renal failure (ERF) and
co-morbid conditions (including estimation of the Charlson
Comorbidity Index (CCI) scores) were recorded. We also re-
trieved data on the last serum creatinine prior to FeMRA and
calculated the eGFR using the six-variable Modification of
Diet in Renal Disease (MDRD) formula [6].
CTA examinations were reviewed for patients who had had
both imagingmodalities performed as part of their assessment,
and served as the reference standard for comparisons with
FeMRA. Direct comparisons of predefined cross-sections of
various vascular beds were performed to visually assess image
quality. The CT and MR images were interpreted separately
and the observer was blinded to patient identity, clinical find-
ings and findings of the other imaging study.
MRI protocol
Patients underwentMRAwith ferumoxytol administered in an
appropriate setting under supervision of trained medical per-
sonnel and were observed for a minimum period of 30 min
following termination of ferumoxytol infusion.
All studies were performed on a 3.0 T Prisma MRI scanner
(Magnetom, SiemensMedical Solutions, Erlangan, Germany)
with local phased-array imaging coils using a standardised
protocol similar to that of standard MRA studies with
GBCAs. All patients were imaged in the supine position.
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Ferumoxytol administration
Ferumoxytol was infused intravenously through a 22-gauge
intravenous catheter placed in the antecubital fossa of either
arm. A total dose of 4 mg/kg of ferumoxytol (Feraheme;
AMAG Pharmaceuticals, Inc., Cambridge, MA, USA) was
delivered up to a maximum of 300 mg. The dosage of
Feraheme is expressed in terms of mg of elemental iron, with
each ml of Feraheme containing 30 mg of elemental iron. In
all cases ferumoxytol was diluted to a concentration no greater
than one part ferumoxytol to four parts 0.9% sodium chloride
and was administered in four equally divided controlled infu-
sions until the full standard dose was delivered. Ferumoxytol
infusions were delivered by an MRI-compatible infusion
pump for precise control over infusion rates. These were set
at 1 ml/s of diluted ferumoxytol (equal to 6 mg/s of elemental
iron) followed by 20 ml of 0.9% sodium chloride at a rate of
2 ml/s.
Patients were instructed to immediately alert the operator
should they have any feelings of discomfort at any time.
Patients were continuously monitored by pulse oximeter
(measuring both heart rate and oxygen saturation) while in
the MRI scanner and had blood pressure measured before
and after infusions. Care was taken to ensure that the total
cumulative dose was not administered in less than 20 min.
Average scan duration was approximately 45 min.
Image acquisition
Pre-contrast imaging was performed for morphological as-
sessment. First-pass, breath-hold imaging with a dynamic
contrast-enhanced technique was performed 15–20 s after de-
livery of the first infusion. These 3D, T1-weighted ultrafast
spoiled gradient echo sequences were also obtained after each
subsequent infusion and were considered first-pass (arterial
phase) images. Further T1-weighted spoiled gradient echo
sequences were used to obtain steady-state breath-hold
(1mm isotropic) and non-breath-hold higher spatial resolution
(0.5 mm isotropic) abdominopelvic images after the first and
each subsequent infusion until the full dose had been reached
– each imaging initiated 3 min after contrast administration.
Data analysis
Both arterial and venous structures were assessed. The exam-
ined arteries included abdominal aorta, coeliac artery, superior
and inferior mesenteric arteries, renal arteries, and common,
external and internal iliac arteries. The examined veins includ-
ed inferior vena cava, renal veins, common, external and in-
ternal iliac veins, and common, superficial and deep femoral
veins in the upper thigh. Visual assessment of the subjective
image quality was performed independently by two radiolo-
gists (M.H and G.R.) with 5 years and >20 years of
experience, respectively, in cardiovascular MR imaging.
Image quality was assessed following administration of the
full cumulative dose and was rated on a scale of 1–4 (1:
non-diagnostic; 2: poor definition such that only gross features
such as overall patency are evaluable; 3: good definition such
that pathology can be confidently visualised or excluded; 4:
excellent definition such that detailed anatomy is clearly
visualised with sharp borders for all vessels) with respect to
the abdominal aorta, the inferior vena cava and the common,
external and internal iliac arteries and veins. The same vessels
were used for comparisons with CTA studies. Interobserver
agreement was calculated using weighted kappa statistics
(<0.2: poor agreement; 0.2–0.4: fair agreement; 0.41–0.6:
moderate agreement; 0.61–0.8: good agreement; 0.81–1.0:
very good agreement). The IBMSPSS Statistics Package (ver-
sion 22.0; SPSS, Inc., Armonk, NY, USA) was used for all
analyses.
Results
A total of 20 patients had FeMRA as part of their pre-
operative kidney transplant assessment. Eight (40%) were
haemodialysis patients. The mean age was 61.2 (standard de-
viation (SD) 11.5) years, 85% were men and 60% were dia-
betic. All patients had a high burden of co-morbidity and only
one patient did not have diabetes, documented atherosclerotic
vascular disease or heart failure. Nineteen (95%) patients had
a high CCI (greater than 2) and, of those, 50% had a very high
CCI (greater than 4) (Table 1). In four patients, arterial vascu-
lar anatomy had been examined with CTA prior to FeMRA.
All subjects completed first-pass and steady-state MRA
acquisitions with ferumoxytol enhancement. There were no
adverse events associated with ferumoxytol administration.
The imaging parameters for the post-contrast breath-hold
MRA acquisitions are listed in Table 2.
Image quality on steady-state acquisitions was scored as
grade 4 in 245 of 320 (76.6%; 90% confidence interval (CI)
72–79) and grade 3 in 75 of 320 (23.4%) vascular sections (at
least diagnostic quality) when assessing the arterial and ve-
nous vasculature by both readers. There were no arterial ana-
tomical characteristics or lesions of clinical significance that
were identified on CTA and not on FeMRA, and vice versa.
There was very good agreement on all individual assessments
of image quality (kappa = 0.85 on assessment of the arteries;
kappa = 0.76 on assessment of the veins; and kappa = 0.93 on
assessment of the arteries on CTA vs. FeMRA).
Following each dose increment, signal intensity and image
quality were improved in both arterial and venous compart-
ments (Fig. 1). First-pass acquisitions showed selective arte-
rial enhancement, with both arterial and venous enhancement
on delayed acquisitions (Fig. 2A, B). Selective venous
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imaging was obtained by subtraction of arterial phase images
from steady-state images (Fig. 2C).
A patient with extensive vascular disease was found to
have bilateral renal artery and infrarenal abdominal aorta
stenosis/occlusions and underwent aorto-bifemoral stent
grafting followed by stenting of the left main renal artery
(Fig. 3). Interesting anatomical variants were illustrated in a
patient with a dual inferior vena cava (Fig. 4) and one with a
retro-aortic left renal vein (Fig. 5). Two patients in this series
were found to have incidental complex renal cysts of the na-
tive kidneys that had enhancing components with ferumoxytol
(Fig. 6); both of these were later confirmed to be renal cell
carcinomas on histology.
Discussion
We applied an MRA technique using intravenous iron as
ferumoxytol to assess vessel characteristics, patency and
course in a series of patients with severely impaired renal
function or on dialysis whilst planning renal transplantation.
Study participants underwent FeMRA as part of their clinical
care instead of or in addition to standard imaging tests. We
administered a total of 4 mg/kg of diluted ferumoxytol in
divided infusions and achieved good signal intensity and im-
age quality with absence of any adverse events. The informa-
tion gained from synchronous depiction of arterial and venous
compartments using a single investigation is essential when
planning kidney transplantation. In a subgroup of patients
who had both FeMRA and CTA performed, FeMRA was
not limited by calcification in assessing the arterial lumen
and it was better for venous evaluation compared to CTA.
Vascular disease is almost universal in potential kidney
transplant recipients, the evaluation of which is important in
planning transplantation. Doppler US is often not appropriate
for evaluation of the deep vessels of the abdomen and pelvis
and calcification further interferes with US assessment of the
arterial vasculature. CTA of the aorto-iliac vasculature has
been shown to allow better recipient selection and accurate
planning for the arterial anastomosis [7], but is limited by
calcification and also does not robustly evaluate venous anat-
omy. This latter limitation is of particular importance as fre-
quently indwelling femoral vein catheters will have been
employed and may have resulted in venous stenosis. MRI is
limited by the concerns around potential development of NSF
when high-risk linear chelate GBCAs are used. Practitioners
are advised against the use of all linear GBCAs in patients
with acute kidney injury or CKD with an eGFR <30 ml/min/
1.73 m2. On the other hand, although NSF seems not to be a
risk with more stable gadolinium agents such as the cyclic
chelates, residual concerns have constrained use. Lastly, con-
ventional invasive angiography is usually reserved for use in
the setting of possible endovascular intervention or targeted
angiography when lower volumes of iodine-based contrast
medium can be used in patients with CKD.
The risks of post-contrast acute kidney injury (AKI) have
been questioned in recent publications [8, 9], although this
remains controversial. Notably, in a series of similar design
retrospective studies, McDonald and colleagues examined the
rate of AKI in the 24–72 h after intravenous contrast-enhanced
Table 1 Demographic and clinical characteristics of patients
Age (y), mean (SD) 61.2 (11.5)
Male sex, n (%) 17 (85.0)
Cause of ERF
Diabetes, n (%)
Renovascular, n (%)
Othera, n (%)
Unknown aetiology, n (%)
9 (45.0)
4 (20.0)
4 (20.0)
3 (15.0)
Co-morbidity
Diabetes, n (%)
Vascular diseaseb, n (%)
Heart failure, n (%)
None of the above, n (%)
12 (60.0)
16 (80.0)
3 (15.0)
1 (5.0)
Charlson Comorbidity Index (CCI) score
CCI 1–2, n (%)
CCI 3–4, n (%)
CCI ≥5, n (%)
1 (5.0)
9 (45.0)
10 (50.0)
eGFR at time of scanc (ml/min/1.73 m2), mean (SD)
Dialysis, n (%)
<15, n (%)
15–29, n (%)
14.0 (4.5)
8 (40.0)
8 (40.0)
4 (20.0)
a Glomerulonephritis (n = 2), autosomal dominant polycystic kidney dis-
ease (n = 1), congenital renal dysplasia (n = 1)
b Coronary artery disease, cerebrovascular disease, peripheral vascular
disease
c Excludes eight patients on dialysis
SD standard deviation, ERF established renal failure, eGFR estimated
glomerular filtration rate; CT computed tomography
Table 2 Pulse sequence parameters for the T1-weighted 3D spoiled
gradient echo sequences (post-contrast)
Repetition time (ms) 2.88
Echo time (ms) 1.04
Flip angle (°) 20
Slice thickness (mm) 1.0
Voxel dimensions (mm) 1.0 x 1.0 x 1.0
Field of view (mm) 400
Acquisition matrix 243 x 384
Timing of sequencea (s) 60
Acquisition Time (s) 18
Signal averages 1
Mean volume thickness 112
Bandwidth (Hz/pixel) 300
Parallel imaging acceleration factor 3
a After start of contrast infusion
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CT or non-contrast-enhanced CT imaging [10–13]. Although
diminished eGFR was associated with an increased risk of
AKI and patients who developed AKI had higher rates of
dialysis and mortality, the occurrence of these outcomes did
not differ significantly between the contrast and non-contrast
group in these studies. Nevertheless, these studies should be
interpreted with caution as despite matching, in a retrospective
study there may have been bias present in selection of the
controls, which may erroneously underestimate or even ob-
scure the real effects of contrast medium. Because of its large
molecular weight of approximately 750 kD, ferumoxytol is
not filtered by the glomerulus, but rather is removed from
the circulation via phagocytosis by macrophages, and subse-
quently broken down. Following macrophage breakdown, the
remaining iron oxide particles are taken up by the reticuloen-
dothelial system, in particular the liver, spleen and bone mar-
row. The distribution of USPIO and conventional GBCAs is
different, with the former remaining in the blood pool prior to
largely redistributing to the reticuloendothelial system, where-
as the latter distributes into the extracellular space after a rel-
atively short time within the blood pool. With ferumoxytol,
arteries and veins can be selectively depicted in a single
examination. Additionally, the prolonged intravascular half-
life (>14 h) of ferumoxytol allows for a longer time window
for data acquisition, higher spatial resolution during the equi-
librium phase and repeat imaging, if necessary, with negligible
loss of intravascular signal intensity [14–16]. On the down-
side, the agent can be present in the blood pool for weeks
following administration and months in the reticuloendotheli-
al system, potentially complicating the appearance of follow-
up studies [17]. A previously described susceptibility artefact
mimicking vascular thrombosis [18] related to higher concen-
trations of ferumoxytol was not observed in our study. In that
study the authors used imaging sequences primarily intended
for parenchymal evaluation rather than MR angiography,
higher concentrations of ferumoxytol (up to 0.43 vs. 0.2 ml/
ml total volume), longer echo times (1.8 vs. 1.0 ms) and
slower infusion rates (2 vs. 1 ml/s), all potentially associated
with susceptibility artefact.
Ferumoxytol has a good safety profile and no known long-
term toxicity [19]. Adverse events with regard to cardiovas-
cular, infectious and mortality outcomes have been shown to
be similar compared with the more commonly used intrave-
nous iron formulations (iron sucrose and ferric gluconate)
Fig. 2 Ferumoxytol-enhanced
magnetic resonance angiography
(FeMRA) of abdominal and
aorto-iliac vasculature in patient
referred for kidney transplant
evaluation. (A) Steady-state ac-
quisition showing enhancement
of both arterial and venous vas-
culature. (B) First-pass imaging
showing selective arterial en-
hancement (arteriography). (C)
Steady-state acquisition showing
selective venous enhancement af-
ter subtraction of the arterial
compartment (venography)
Fig. 1 Arterial phase maximum intensity projection (MIP) images of
abdominal and aorto-iliac vasculature after each increment of
ferumoxytol. (A) Pre-contrast and after administration of (B) 1 mg/kg,
(C) 2 mg/kg, (D) 3 mg/kg and (E) 4 mg/kg of ferumoxytol. Both arterial
and venous compartments enhance due to contrast pooled intravascularly
from previous infusions
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[20]. Although the reported incidence of adverse reactions is
higher with ferumoxytol than with GBCAs, the rates of these
in clinical trials and post-marketing safety data on therapeutic
use of ferumoxytol are very low [5, 21–23]. Most reported
adverse events were mild, transient and typically associated
with the infusion process, although mild arthralgia/myalgia
and headaches occurred up to 48 h post-infusion in one study
[23], where 1.02 g of ferumoxytol was administered over
15 min. Serious adverse events included hypersensitivity
[22, 24] and hypotension [24] with a pooled aggregate rate
of anaphylaxis of 0.03% (3/10,425) based on published stud-
ies [5, 21, 22, 24]. The main concern has been reported cases
of anaphylactic-type reactions with therapeutic bolus injec-
tions of undiluted compound leading to the recent recommen-
dations for controlled infusion of dilute ferumoxytol. Rather
than true allergy it is thought this is a chemotoxic
phenomenon related to high concentrations of the iron com-
pound when infused rapidly interacting with mast cells in the
vascular wall [25]. Since 2009, approximately 1.2 million
therapeutic doses of ferumoxytol have been administered. In
March 2015, the US Food and Drug Administration (FDA)
Adverse Event Reporting System reported 79 anaphylactic
reactions, of which 18 were fatal. These deaths resulted in a
boxed warning in March 2015 (http://www.fda.gov/Drugs/
DrugSafety/ucm440138.htm). Twenty-four percent of these
patients had multiple drug allergies, and nearly half of these
anaphylactic reactions occurred within 5 min of administra-
tion. This rate of adverse events is lower than the rates initially
reported in Phase II–III clinical trials. When given for treat-
ment of IDA, the licensed dose of ferumoxytol is an initial
510-mg dose administered as an intravenous infusion, follow-
ed by a second 510-mg dose 3–8 days later. We used only a
Fig. 4 (A) Steady-state acquisi-
tions with ferumoxytol-enhanced
magnetic resonance angiography
(FeMRA) in an individual with an
anatomical variant of a dual infe-
rior vena cava (arrowheads). (B)
Three-dimensional reconstruction
of abdominal vasculature at the
level of the inferior vena cava
duplication
Fig. 3 (A) Ferumoxytol-enhanced magnetic resonance angiography
(FeMRA) in an individual with a tightly stenosed left main renal artery
(dashed arrow), a small patent accessory renal artery (solid arrow), and an
occluded right renal artery (‡) and infrarenal abdominal aorta (*). (B)
Digital subtraction angiography (DSA) after aorto-bifemoral stent
grafting showing the tightly stenosed left main renal artery. (C) Three-
dimensional reconstruction of aorta and inferior vena cava at the level of
bifurcation of renal arteries
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fraction of the therapeutic dose (approximately a quarter of the
full dose for a 70-kg adult), much-diluted and slowly infused
(in 5-min intervals between pulsed infusions) to minimise the
risk of reaction, and this was proven more than adequate for
vascular imaging. It is important to note that the above risks
have parity with the other commonly administered intrave-
nous radiological contrast media (whether iodine or gadolini-
um-based), therefore patients were not exposed to dispropor-
tionate risk. Hence, ferumoxytol has the potential to be used
for clinical vascular imaging beyond investigational use in
patients with contraindications to GBCAs, such as renal fail-
ure and known GBCAs allergies.
Dose-related efficacy studies are lacking, hence different
doses have been reported in the literature, ranging from
120 mg of elemental iron in a bolus solution for angiographic
assessment of arteriovenous fistulae [26] to 6 mg/kg for kid-
ney mapping [27]. We used a comprehensive protocol admin-
istering a total of 4 mg/kg of ferumoxytol diluted fourfold with
normal saline and delivered in four equally divided infusions
over a minimum of 20 min and we observed no significant
blunting in signal intensity.
Others have studied MRA using ferumoxytol as contrast in
patients with kidney disease. Sigovan et al. [26] found that
FeMRA provided better image quality and reduced flow
Fig. 6 Ferumoxytol-enhanced
magnetic resonance angiography
(FeMRA) showing incidental re-
nal tumours in two patients. (A)
Coronal pre- and (B) post-
contrast T1-weighted first-pass
acquisitions through the upper
abdomen showing tumour with
peripheral enhancement and cen-
tral necrosis originating from the
lower pole of the right kidney. (C)
Transverse pre- and (D) post-
contrast T1-weighted first-pass
acquisitions through the upper
abdomen from another patient
showing a large partially enhanc-
ing right renal mass (arrows)
Fig. 5 Abdominal and aorto-iliac
vasculature in a patient referred
for kidney transplant assessment.
(A) Coronal CT angiogram
through the upper abdomen
showing foci of calcification at
the aortic sector and iliac arteries.
(B) Steady-state FeMRA of the
same patient with synchronous
illustration of aorto-iliac sector
and inferior vena cava. (C)
Anterior and (D) posterior views
of three-dimensional reconstruc-
tion of abdominal and aorto-iliac
vasculature showing an anatomi-
cal variant of a low-lying retro-
aortic left renal vein (arrow)
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artefacts compared to non-contrast MRA in dialysis fistula
evaluation, with a much shorter acquisition time (19 vs.
270 s). FeMRA has been used in kidney transplant recipients
with graft dysfunction, where steady-state imaging was better
for evaluation of transplant vasculature compared to first-pass
imaging [28] and better for detection of graft artery abnormal-
ities compared to US [29]. When compared with digital sub-
traction angiography (DSA), FeMRAwas similarly sensitive
and accurate in assessing the severity of transplant renal artery
stenosis [30]. In a comparative study of ferumoxytol-
enhanced versus gadofosveset-enhanced MR venography for
abdominopelvic and lower extremity venous assessment,
there was no difference in signal intensity between the two
techniques [31]. In two paediatric cohorts of 30 children with
CKD who needed detailed vascular mapping for various indi-
cations (i.e. vascular access planning or complication, pre- or
post-kidney transplant evaluation), FeMRA examinations
were reported to be diagnostic and safe [32, 33]. Apart from
vascular imaging, ferumoxytol-based imaging has been suc-
cessfully used for the delineation of primary pancreatic tu-
mours [34] and as an ionising radiation-free staging method
in children and young adults with malignant lymphomas and
sarcomas [35]. In our study, ferumoxytol-enhancing complex
renal cysts were detected in two patients; both proved to be
renal cell carcinomas.
The main limitations of this study are the single-centre
design with a relatively small number of patients and lack of
consistent reference standard. However, the purpose of this
study was to address the technical feasibility of acquiring ad-
equate abdominal and aorto-iliac vascular enhancement with a
non-nephrotoxic, high relaxivity contrast agent in patients be-
fore wait-listing for kidney transplantation. Four patients had
both CTA and FeMRA performed and although some com-
parisons were made, the study was not designed to estimate
accuracy, sensitivity and specificity of the two different imag-
ing techniques. A formal prospective study directly compar-
ing the diagnostic accuracy of FeMRAversus CTA is current-
ly recruiting in our centre (Clinicaltrials.gov identifier:
NCT02997046).
High concentrations of the agent can cause artefacts be-
cause of signal loss through T2* shortening, and care must
be taken to inject a low enough concentration to avoid this
pitfall. Therefore, we used small cumulative increments of
ferumoxytol but in this preliminary report on 20 subjects the
number of patients was not large enough to establish the de-
finitive optimal (minimum) dose required to achieve adequate
diagnostic accuracy. However, our preliminary findings indi-
cate that the administration of doses >3 mg/kg does not im-
prove image quality (unpublished data). Despite being a case
series, sequential enrolment minimised selection bias. In ad-
dition, differences in exposure to ferumoxytol wereminimised
by the use of a consistent protocol with standardised infusion
rates and imaging parameters. Using a consistent dosing
regimen for contrast administration, we have shown that
ferumoxytol-based vascular imaging has the potential to offer
a clinically useful and reliable alternative in renal patients in
whom standard imaging methods cannot be used.
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